Home > Back to Publisher > Report Information

Stakeholder Opinions: Type 2 Diabetes in the UAE & Saudi Arabia Growth opportunities in fragmented markets

Datamonitor
December 19, 2008
27 Pages - SKU: DFMN2069254

Abstract Table of Contents Related Reports

Countries covered: Saudi Arabia, United Arab Emirates

Introduction

This report focuses on the challenges of diverse and uncoordinated treatment paradigms for diabetes and the movement to rationalize efforts and establish best practice. Datamonitor uncovers the unique dynamics of the two largest diabetes markets in the GCC; including the impact of regulatory processes such as the healthcare reforms currently being undertaken.

Scope

Description and analysis of the uniqueness of the antidiabetic markets in the UAE and Saudi Arabia
Fragmented healthcare delivery in the UAE and Saudi Arabia presents opportunity for ramping up sales of generics and novel antidiabetic therapeutics.
Commercial implications of Datamonitor's extensive findings and our recommendations to maximize sales in these two markets.

Highlights

Diabetes has reached near-epidemic proportions in the UAE and Saudi Arabia, with nearly one out of every five individuals suffering from diabetes in the UAE. In Saudi Arabia, the prevalence is expected to rise to between 40-50% by 2020.

The delivery of treatment for diabetes is highly fragmented, and leads to sub-optimal treatment for patients in the two countries. The fragmentation is caused by a wide variety of issues due to systemic deficiencies, regulatory changes and socio-economic factors.

Datamonitor has explained the commercial implications of its findings and developed recommendations for healthcare firms and regulators to address the many unmet needs in the treatment of diabetes and to ramp up sales and share of market in both UAE and Saudi Arabia.

Reasons to Purchase

Gain an in-depth understanding of the two largest diabetes markets in the GCC; a strategic growth area for healthcare firms.
Increase share of the market by effectively targeting the different segments of the population and demands; branded or generic antidiabetic agents.
Maximize current and future revenue streams by targeting the numerous growth opportunities identified by Datamonitor.

ABOUT DATAMONITOR HEALTHCARE: About the Cardiovascular pharmaceutical analysis team
CHAPTER 1 EXECUTIVE SUMMARY: Scope of the analysis; Datamonitor insight into type 2 diabetes in the UAE and Saudi Arabia; Related reports; Upcoming reports; Key Opinion Leaders Interviewed
CHAPTER 2 DEFINITION OF DIABETES AND DISEASE OVERVIEW: Definition of diabetes; Segmentation of diabetes; Type 1 diabetes; Type 2 diabetes; Etiology of diabetes; Mechanisms of development of diabetes; Genetic or acquired causes; Risk factors; Obesity; The type 2 diabetes epidemic goes hand-in-hand with the obesity epidemic.; Family history; Type 2 diabetes in first-degree relatives is a strong prognostic indicator; Advanced age; Diagnosis of type 2 diabetes may be overlooked in older patients; Gender; Risk of type 2 diabetes may be greater in females; History of prediabetes; Physical inactivity; Diet and western lifestyle; Arab and South Asian genetic susceptibility; Consanguinity and thalassemia minor are risk factors for diabetes.; Other factors; Socio-economic traditions; The role of alcohol and fasting blood glucose; Vitamin D deficiency and diabetes; Epidemiology; Increasing prevalence of diabetes in the GCC; Economic burden of diabetes
CHAPTER 3 DIAGNOSIS OF TYPE 2 DIABETES: Diagnosis of type 2 diabetes; Patient management; Management of diabetes should be done by a team, not just a specialist; Healthcare provision in Saudi Arabia is highly fragmented; Abu Dhabi and Dubai have excellent healthcare facilities, but the northern emirates are lagging behind.; Abu Dhabi; Dubai; The role of PCPs in type 2 diabetes management; Referral to specialist; Reasons for poor diagnosis; Insidious nature of the disease; Lack of screening; Awareness of guidelines; Strategies to increase diagnosis rates; Improving guideline awareness of PCPs; There is a need for a targeted screening program; Strategies to prevent diabetes; Preemptive treatment; Education in the UAE; Building awareness of diabetes in Saudi Arabia
CHAPTER 4 DIABETIC COMPLICATIONS: Complications of diabetes; Nephropathy; Effect of nephropathy on type 2 diabetes treatment; Retinopathy; Effect of retinopathy on type 2 diabetes treatment; Neuropathy; Effect of neuropathy on type 2 diabetes treatment; Macrovascular complications; Effect of macrovascular complications on type 2 diabetes treatment; Co-morbidities; Obesity; Effect of obesity on type 2 diabetes treatment; Hypertension; Dyslipidemia
CHAPTER 5 CURRENT TREATMENT OPTIONS FOR TYPE 2 DIABETES: International treatment guidelines for type 2 diabetes; Clinical practice guidelines from the ADA/EASD; The AACE-ACE clinical practice guidelines; Guideline use in the UAE and Saudi Arabia; Treatment patterns; Lifestyle management for type 2 diabetes; Pharmacological treatment; In Saudi Arabia, the new classes of antidiabetics are not yet approved and most branded drugs are not available in MOH primary care centers; KOLs in the UAE are very satisfied with the pharmacological options available for use; Insulin use in Saudi Arabia is limited by the types available to physicians; Alternative and adjunct therapies; Prescribing trends and influences; Slow approvals by the SFDA and the exlusion of drugs from MOH formularies hampers prescription in Saudi Arabia, while the latest drugs are available to physicians in the UAE.; Nationality influences the standard of care available; Self-management
CHAPTER 6 UNMET NEEDS: Limited availability of drugs; The need to build awareness of diabetes, obesity and healthy lifestyle; The need for diabetes education teams; Guideline awareness of PCPs; Patient compliance
CHAPTER 7 COMMERCIAL IMPLICATIONS OF FINDINGS AND RECOMMENDATIONS: GCC is a strategic growth region; Growth through partnerships with regional players; Dubai has created a favorable landscape for foreign healthcare investment; The antidiabetic markets in the UAE and Saudi Arabia are unique; The UAE is very receptive to new antidiabetic drugs and is brand-conscious; The Saudi Arabian market is plagued by slow approvals; Treatment paradigms are highly diverse in the UAE and Saudi Arabia; Use of different guidelines and poor adherence to them; Lack of access to newer antidiabetic therapies in Saudi Arabia; Insufficient insurance coverage impedes delivery of optimal treatment in the UAE; Domestic pharmaceutical sectors; The local pharmaceutical firms in UAE and Saudi Arabia are export-oriented; UAE; Saudi Arabia; Regulatory environments; The privatization of payment will favor generics in the long term; Slow approval procedures in Saudi Arabia; Guideline development is critical in both countries; Recommendations for local and regional generics pharmaceuticals; Recommendations for multinational pharmaceutical companies; Recommendations for healthcare regulators
APPENDIX: About Datamonitor; About Datamonitor Healthcare; About the Disease analysis team; Disclaimer
List of Tables: Table 1: Summary of differences between type 1 and type 2 diabetes; Table 2: Current prevalence of type 2 diabetes, GCC; Table 3: ADA evidence grading system for clinical practice guidelines; Table 4: AACE recommendations for type 2 diabetes patients naïve to pharmacotherapy; Table 5: AACE recommendations for type 2 diabetes patients currently on pharmacotherapy
List of Figures: Figure 1: Percentage of overweight adults aged 15 and over, GCC; Figure 2: Top 10 countries in prevalence of diabetes (20-79 age group); Figure 3: Current prevalence of diabetes and forecasts for 2025; Figure 4: Treatment algorithm for type 2 diabetes, recommended by the 2006 ADA/EASD clinical practice guidelines; Figure 5: The proportion of diabetics in each GCC country; Figure 6: Population pyramid for Saudi Arabia: 2010; Figure 7: Population pyramid for Saudi Arabia: 2020; Figure 8: Population pyramid for UAE: 2010; Figure 9: Population pyramid for UAE: 2020; Figure 10: UAE pharmaceutical sector sales segmentation; Figure 11: Saudi pharmaceutical sales segmentation

More United Arab Emirates Reports

D&B Country RiskLine Report: The United Arab Emirates by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...

D&B Country Report: The United Arab Emirates by Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...

Country Report United Arab Emirates January 2011 by Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...

United Arab Emirates: Country Profile by MarketLine
INTRODUCTION This report provides a detailed analysis on the United Arab Emirates (UAE), providing an overview of its political, economic and business environment, represented both textually ...

Country Insight - United Arab Emirates Q3 2006 Report by Noozz Research
This Noozz Research Report offers a valuable perspective upon developments in the UAE marketplace. This report contains the latest analysis on the political and economic ...

See all reports like this >>

Stakeholder Opinions: Type 2 Diabetes in the UAE & Saudi Arabia Growth opportunities in fragmented markets

Share this report

Other tasks

Research Assistance

Related Markets

Drug Discovery Reports

Free Alert Me service